Effectiveness of Midodrine as an Adjuvant to Norepinephrine in Weaning Critically Ill Patients From Vasopressors

Not Applicable

Recruiting

• Conditions: Shock
• Interventions: Drug: Weaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine; Drug: Weaning critically ill patients from norepinephrine without use of midodrine as an adjuvant

• Registration Number: NCT06930235
• Lead Sponsor: Sohag University

Brief Summary

This study aims to evaluate the effectiveness of midodrine as an adjuvant to norepinephrine in weaning critically ill patients from vasopressors

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study Start: 2025-03-13
• Study First Submitted: 2025-04-08
• Study First Submitted QC: 2025-04-08
• Last Update Submitted: 2025-04-08
• Study First Posted: 2025-04-16
• Last Update Posted: 2025-04-16
• Primary Completion: 2025-10-13
• Study Completion: 2025-10-13

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

• Patients with refractory hypotension on an intravenous vasopressor for more than 24 h but deemed clinically stable.
• Patients on noradrenaline support <10 μg/min

Exclusion Criteria

• Known allergy to midodrine.
• Severe shock state, as evidenced by multiple vasopressor infusions or high vasopressor requirement (i.e. noradrenaline >10 μg/min)
• Patients with severe organic heart disease (e.g., heart failure, sever aortic stenosis), pregnancy, thyrotoxicosis or pheochromocytoma.
• Those with no enteral route available.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Weaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine	Weaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine	Patients in group I will receive midodrine (10 mg orally every 8 hours) in addition to administered concurrently with ongoing intravenous norepinephrine after being on norepinephrine for more than 24 h.
Weaning critically ill patients from norepinephrine without use of midodrine as an adjuvant	Weaning critically ill patients from norepinephrine without use of midodrine as an adjuvant	Patients in group II with ongoing intravenous norepinephrine only

Primary Outcome Measures

Name	Time	Method
follow up of critically ill patients on vasopressors	48 hours	time of weaning from intravenous vasopressor (norepinephrine)

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt